Horizon Discovery Share Discussion Threads

[jurgenklopp] 15/10/2018 10:56

I assume Woodford has sold 3,900,000 shares to ValueAct.

ValueAct have a reputation for being long term, supportive holders, so very good news for holders but maybe not for short term wheeler dealers.

At current levels the shares would appear to be very good value.

[bouleversee] 15/10/2018 10:42

So the share price takes a steep vertical dive! Explain, please.

[jurgenklopp] 15/10/2018 10:30

ValueAct have doubled their stake to 10%.

[danieldanj] 04/10/2018 12:17

Horizon Discovery (HZD) News Out Just Now

[bouleversee] 18/9/2018 18:14

I wonder why Woodford has reduced his fund's holding.

[kestelmill] 18/9/2018 16:20

In the slides it says £1.4M investment into Avvinity post-period end. I would like to more info regarding how that project is developing given that level of investment

[gersemi] 18/9/2018 08:43

Wot's going on here?

[rambutan2] 18/9/2018 02:40

Yesterday's interims presentation:

[rambutan2] 18/9/2018 02:17

Bit more meat on the bone here:

[bouleversee] 17/9/2018 11:56

The chart on my ii account is showing a vertical drop to 2.14 at 11 a.m. and immediately back up again. What do you suppose went on there?

[jurgenklopp] 17/9/2018 11:25

Could be ValueAct topping up !!

7.4 million shares is a tremendous show of faith from someone.

;o)

[mamcw] 17/9/2018 11:19

5% of the HZD's shares have just traded, with a huge amount of other activity as well. New shareholdings disclosures should make interesting reading in the next couple of days.

[mamcw] 17/9/2018 07:16

An upbeat tone to the results. Outlook statement positive, with a please upgrade to analysts revenue expectations and positive EBITDA in H2

"We are excited at the opportunities ahead of the Group as gene editing becomes broadly adopted at industrial scale. We have implemented a new investment strategy, prioritising our identified core growth areas of business, supported by a long-term investment plan that will help drive the scale necessary to meet market demand and fulfil the significant growth potential of the business.
We have made a strong start to trading in the second half of the year, including significant new customer relationships in CRISPR screening, continued momentum in our applied products business and a positive trajectory from our research products. We anticipate a second half weighting of revenues in line with previous years, with full year revenues slightly ahead of consensus expectations"

[jurgenklopp] 14/9/2018 11:09

Shouldn't there be an RNS for this ?

Pretty good news.

[mamcw] 14/9/2018 10:48

14/09/2018 9:27am
Business Wire

Horizon Discvry (LSE:HZD)
Intraday Stock Chart
Today : Friday 14 September 2018

Click Here for more Horizon Discvry Charts.
AstraZeneca joins Horizon’s Genomics Discovery Initiative
CRISPR knockout and activation libraries are a key toolset in early research
crRNA libraries are an efficient and convenient platform for gain- and loss-of-function studies
Horizon Discovery Group plc (LSE: HZD) (“Horizon̶1; or “the Company”), a global leader in gene editing and gene modulation technologies, today announces AstraZeneca has adopted its Edit-R™ crRNA libraries as part of AstraZeneca’s drive to establish a functional genomics discovery platform. AstraZeneca also joins the Genomics Discovery Initiative (GDI), a collaborative functional genomics screening community facilitated by Horizon.

AstraZeneca has been evaluating Horizon’s Edit-R human whole genome crRNA library for gene knockout since late 2017, and will soon add the Company’s platform of arrayed synthetic crRNA libraries for CRISPR-mediated transcriptional activation (CRISPRa). The libraries offer a powerful tool for functional genomic screens in drug discovery, providing deeper insight into biological mechanisms for the purpose of understanding disease progression, host-pathogen relationships, drug interactions, and pathway analysis.

Horizon’s Edit-R CRISPR-Cas9 synthetic crRNA libraries for both knockout (loss-of-function) and activation (gain-of-function) enable whole genome analysis in an arrayed format, allowing researchers to carry out high-content, multiparametric analyses on a one-well-per-gene basis. The portfolio includes catalog libraries for popular human and mouse gene families, in addition to druggable gene targets and the whole human genome. Bespoke collections are also available to support researchers working with a specialized gene target list.

Terry Pizzie, Chief Executive Officer, Horizon Discovery, commented: “Our ongoing relationship with AstraZeneca is providing valuable insights into the scope and capabilities of CRISPR screening, which will be of benefit to the research and discovery community, ultimately bringing drugs to market faster.”

Steve Rees, Head of Discovery Biology, IMED Biotech Unit at AstraZeneca, said: “The scientific support and degree of collaboration with the scientists at Horizon has been really impactful in ensuring we are able to harness the full potential of the platform. We have been impressed with the performance of the Edit-R synthetic crRNA, and look forward to feeding our drug discovery pipeline with data generated from the CRISPRa crRNA libraries.”

[mamcw] 11/9/2018 09:34

a key number to look out for is the revenue forecast for 31/12/18. At the time of the Abcam approach, HZD effectively put out a revenue forecast of £60m for this year, being the consensus of broker forecasts. At the least, this need to be reaffirmed in the outlook statement.

[jurgenklopp] 10/9/2018 09:15

Results are next Monday - the 17th.

[mamcw] 06/9/2018 11:47

Yup. Feel that HZD's time has finally come.

[mamcw] 06/9/2018 08:59

I've taken the view that Woodford, Invesco and ValueAct cannot all of got their due diligence wrong and that HZD is going to deliver. So I've tucked in again at 214p and will sit with this one for the long term.

[rambutan2] 04/9/2018 12:28

Yes, very interesting new holder, and certainly far from passive. The stake has gone into its latest fund, which has a slightly different twist:

[mamcw] 04/9/2018 08:24

We should be honoured. ValueAct have taken a 5% stake. These are the guys who spotted the value in the likes of Rolls Royce and have a reputation for shaking up companies and promoting M&A. Effectively, their stake underpins the current price and might yet gets us north of £3. Watch this space.

[pjj71] 28/8/2018 15:26

LETS HOPE FOR 300P SOON!!!

[mamcw] 28/8/2018 15:00

Hard to work out what is going on. Announcement made at 10am concerning CRISPR partnership; price takes off at 1pm, rally from 190p to 215p.